Mental Health Clinical Trials Market Landscape 2025: Forecast Data and Growth Strategy Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Mental Health Clinical Trials Market Through 2025?
Over the past years, there has been a significant increase in the size of the mental health clinical trials market. This market is expected to escalate from $2.96 billion in 2024 to $3.23 billion in 2025, equating to a compound annual growth rate (CAGR) of 9.1%. The historical growth is a direct result of factors such as heightened interest in the development of neuropsychiatric drugs, increasing incidences of stress, anxiety, and depression, bolstered support from governmental and regulatory institutions, a growing population of the elderly, and a surge in demand for non-pharmacological interventions.

What's the Projected Size of the Global Mental Health Clinical Trials Market by 2029?
The marketplace for mental health clinical trials is predicted to significantly expand in the upcoming years, reaching $4.51 billion by 2029 with a compound annual growth rate (CAGR) of 8.7%. This upward trend during the forecast period can be traced back to various factors such as an increased prevalence of mental health diseases, a heightened awareness about mental health concerns, a surge in the need for individualized medicine, higher expenditure on healthcare, and the growing application of digital health tech. The leading trends for the projected period comprise advancements in digital health platforms, technological progress in wearable devices, cutting-edge neuroimaging technologies, innovations in electronic data capture (EDC) systems, and the transformation towards technology-fueled decentralized clinical trial models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/mental-health-clinical-trials-global-market-report

Top Growth Drivers in the Mental Health Clinical Trials Industry: What's Accelerating the Market?
The growing rate of mental health disorders is predicted to drive the expansion of the market for clinical trials in mental health. These disorders, which significantly impact an individual's emotions, thought patterns, behaviours, and overall mental functionality, are becoming more prevalent due to the escalating stress associated with contemporary lifestyles, including high job pressure, societal isolation, and the omnipresence of digital connections. By assessing the safety and efficacy of new medications, therapies, and behavioural interventions for mental health issues, mental health clinical trials aid in improving care. For example, the American Psychiatric Association, a non-profit organization based in the US, reported in May 2024 that approximately 43% of American adults experienced increased anxiety, up from 37% in 2023 and 32% in 2022. Therefore, the market for mental health clinical trials is growing due to the surging incidence of mental health disorders.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27343&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Mental Health Clinical Trials Market?
Leading companies in the mental health clinical trials market are concentrating on progress in cutting-edge treatments like adjunctive therapies. These treatments aim to boost effectiveness, enhance patient outcomes, and fulfill the unmet needs concerning mental health disorders. In simple terms, adjunctive therapies refer to medications that are used alongside main treatments to increase the handling of intricate conditions. In a notable example, the US-based biopharmaceutical company AbbVie Inc. gained U.S. Food and Drug Administration (FDA) approval for VRAYLAR (cariprazine) in December 2022. The approval was for the use of VRAYLAR as an adjunctive treatment for adults suffering from major depressive disorder. VRAYLAR operates with a unique dopamine-serotonin partial agonist mechanism which adds to the value of traditional antidepressants. It aids in easing depressive symptoms in patients who show an inadequate response to regular therapy. Moreover, the product improves mood stabilization and decreases the side effects typically associated with older antipsychotics.

What Are the Main Segments in the Mental Health Clinical Trials Market?
The mental health clinical trials market covered in this report is segmented

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Other Study Designs
3) By Disorder: Anxiety Disorders, Depression, Bipolar Affective Disorder, Dissociation And Dissociative Disorders, Schizophrenia, Other Disorders
4) By Sponsor: Pharmaceutical And Biopharmaceutical Companies, Government Agencies, Other Sponsors

Subsegments:
1) By Phase I: Single Ascending Dose, Multiple Ascending Dose, First In Human, Pharmacokinetics Studies
2) By Phase II: Dose Ranging Studies, Proof Of Concept Studies, Randomized Controlled Trials, Open Label Studies
3) By Phase III: Large Scale Randomized Trials, Multicenter Studies, Comparative Effectiveness Trials, Double Blind Studies
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies, Pharmacovigilance Studies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27343&type=smp

Which Top Companies are Driving Growth in the Mental Health Clinical Trials Market?
Major companies operating in the mental health clinical trials market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., Precision for Medicine Inc.

Which Regions Will Dominate the Mental Health Clinical Trials Market Through 2029?
North America was the largest region in the mental health clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mental health clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27343

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.